AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
Published on 08/07/2025 at 18:06 | prnewswire.co.uk
to learn more about our transformative approach to immunotherapies.
Company Contact:
Dr. Ann Meulemans, CEO Aboleris
+32479900357
Ann.meulemans@aboleris-pharma.com
Media & Investor Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com
Logo - https://mma.prnewswire.com/media/2671455/AbolerIS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/aboleris-pharma-announces-first-cohort-dosed-in-phase-1-study-of-abo21009-a-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis-302447861.html
en | boerse | 67950966 |
